Earth Science Tech, Inc. (OTC: ETST) announced financial and operational results for the third fiscal quarter ended December 31, 2025, demonstrating significant growth in revenue and profitability. The company reported revenue of $8.4 million, a 14.1% increase year over year, driven by continued expansion across its operating subsidiaries. Gross profit reached $6.4 million, reflecting a robust 76.3% margin, while net income soared 341% to $910,000 compared to the prior-year period. Adjusted EBITDA totaled $1.2 million, underscoring improved operational efficiency.
The company's balance sheet strengthened during the quarter, with total assets increasing to $8.1 million. Earth Science Tech ended the period with $416,000 in cash, $773,000 in working capital, and no bank debt, positioning it for future growth initiatives. During the first nine months of fiscal 2026, the company repurchased and retired 3.7 million shares, demonstrating confidence in its long-term value and commitment to shareholder returns.
Management attributed the strong performance to continued operating leverage and strategic expansion initiatives. The company operates as a strategic holding company focused on value creation through acquisition and operational optimization. Its current operations include compounding pharmaceuticals, telemedicine, and real estate development through wholly owned subsidiaries such as RxCompoundStore.com, LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC, Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC, and an 80% interest in MagneChef.
For more details on the full press release, visit https://ibn.fm/emIBm. To stay updated on the latest news and developments regarding Earth Science Tech, visit the company’s newsroom at https://ibn.fm/ETST.
